NKGen Biotech, Inc.

S.Biomedics’ stem cell therapy for Parkinson’s disease has shown positive results in an assessment of one-year data from the three patients (first low-dose cohort) in a Phase I/IIa clinical trial, rai

Neurological disorders account for roughly 45% of rare diseases; and 85% of rare and ultra-rare disease trace back to a single gene defect. Given this, the potential for regenerative therapies to bene

The usual pattern of reporting positive clinical trial results or winning US Food and Drug Administration approval then launching a large follow-on public offering (FOPO) has become less common under

Biotechnology stocks in the US are still trading lower year-to-date, but valuations have risen significantly in April, suggesting that perhaps the winter chill hovering over the industry is beginning